知镜 Cognispect · 医学文献与研究工作台

Mesenchymal stem cells and empagliflozin: a potential therapeutic approach for autophagy and Klotho modulation in diabetic kidney disease.

Franco ML, Beyerstedt S, Barbosa BS, Alves TR, da Silva AF, Mariano MO, Carlos AKG, Arjona JC, Josefi-Rocha GR, Bastos RMC, Rangel ÉB.
Stem cells (Dayton, Ohio) · 2026-08-01 · PMID 42538821

文献摘要

Background Diabetic kidney disease (DKD), the leading cause of end-stage renal disease, involves injury across multiple renal compartments. Autophagy dysregulation is a key pathogenic mechanism and may reduce Klotho, a renoprotective protein diminished in DKD. This study evaluated whether bone marrow-derived mesenchymal stem cells (MSCs), combined with empagliflozin and calorie restriction, could modulate autophagy and preserve Klotho expression in DKD. Methods Male BTBRob/ob mice, a leptin-deficient model that develops diabetes and DKD in a progressive manner, were assigned to experimental groups and euthanized at 14-15 or 18-20 weeks. Kidney tissues were analyzed by qPCR, Western blot, and immunohistochemistry. Results MSCs therapy improved hyperglycemia in a time-dependent manner (P Conclusion Overall, MSCs combined with empagliflozin and calorie restriction show promise as a translational approach for DKD, warranting further long-term preclinical studies.

在知镜精读原文来源DOI 原文

知镜提供医学文献检索、阅读笔记、人体图谱、统计绘图与研究复现工具。